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Abstract
Human leukocyte antigen (HLA) genes encode proteins with important roles in the regulation of the immune system. Many
studies have also implicated HLA genes in psychiatric and neurodevelopmental disorders. However, these studies usually focus
on one disorder and/or on one HLA candidate gene, often with small samples. Here, we access a large dataset of 65,534
genotyped individuals consisting of controls (N= 19,645) and cases having one or more of autism spectrum disorder (N=
12,331), attention deﬁcit hyperactivity disorder (N= 14,397), schizophrenia (N= 2401), bipolar disorder (N= 1391), depression
(N= 18,511), anorexia (N= 2551) or intellectual disability (N= 3175). We imputed participants’ HLA alleles to investigate the
involvement of HLA genes in these disorders using regression models. We found a pronounced protective effect of DPB1*1501
on susceptibility to autism (p= 0.0094, OR= 0.72) and intellectual disability (p= 0.00099, OR= 0.41), with an increased
protective effect on a comorbid diagnosis of both disorders (p= 0.003, OR= 0.29). We also identiﬁed a risk allele for
intellectual disability, B*5701 (p= 0.00016, OR= 1.33). Associations with both alleles survived FDR correction and a
permutation procedure. We did not ﬁnd signiﬁcant evidence for replication of previously-reported associations for autism or
schizophrenia. Our results support an implication of HLA genes in autism and intellectual disability, which requires replication
by other studies. Our study also highlights the importance of large sample sizes in HLA association studies.
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Introduction
Proteins of the major histocompatibility complex (MHC) in
humans are encoded by the human leukocyte antigen (HLA)
region on chromosome 6. This region is highly dense in genes
and highly polymorphic, and many genetic variants lying
within it have been implicated in human diseases, such as
autoimmune disorders and infections [1]. Proteins encoded by
HLA genes have important roles in immune reaction and are
divided into three classes. In this study, we focus on genes
from HLA classes I and II. HLA class I genes encode proteins
that present endogenous antigens (produced inside the cell),
and HLA class II genes encode proteins that present antigens
from outside the cell to T cells [2]. Although less clear than
the connection between autoimmune diseases and the
immune system, the connection between psychiatric and
neurodevelopmental disorders and the immune system is
supported by increasing evidence in past decades, from
associations of autoimmune diseases and allergies with schi-
zophrenia and autism spectrum disorder (ASD) to dysregu-
lation of immune-related genes or cytokine levels in those
disorders [3]. While many robust associations of HLA genes
with autoimmune diseases have been reported [4], several
class I and class II HLA genes have also been implicated in
psychiatric and neurodevelopmental disorders, albeit with
uneven reproducibility. Speciﬁcally, the A2 allele of HLA-A,
several HLA-B alleles, as well as HLA-DRB1 DR4 have been
reported to be associated with ASD [5–8], the latter also being
associated with attention deﬁcit hyperactivity disorder
(ADHD) [9]. For schizophrenia, associations with many HLA
genes have been reported. In an extensive review [10], Wright
et al. propose that much of the evidence for these associations
is weak due to problems in study design. More recently, a
study reported variants in the C4 loci (part of the complement
system) to be associated with schizophrenia [11]. The invol-
vement of HLA genes in either affective disorders or anorexia
has not been robustly established, with studies mostly
originating from the 1980s and reaching different conclusions
[12–16]. In this study, we test for association between seven
major psychiatric or neurodevelopmental disorders and seven
HLA genes in an unbiased approach, using a genetically
homogeneous sample from the Danish Integrative Psychiatric
Research (iPSYCH) Consortium. Additionally, we attempt to
replicate previously reported associations.
Methods
Participants, SNP arrays, and quality control
procedures
The individuals included in this study are part of the
iPSYCH consortium’s sample of Danish individuals
selected for having a psychiatric diagnosis or as random
population controls [17]. Quality control (QC) procedures
were followed in order to remove individuals of divergent
ancestry and to keep only unrelated cases and controls. This
was achieved by using Danish registry data on family his-
tory and through a genetic principal component analysis
(PCA). Before QC, our sample included 78,050 subjects
genotyped in 23 of the original 25 waves used in subsequent
QC and downstream analyses. The QC procedures leading
to the sub-sample analyzed here were originally performed
for another study and are described extensively elsewhere
[18]. In short, PCAs were performed with the iPSYCH
individuals and several 1000 Genomes samples as a refer-
ence panel: in the ﬁrst step, both datasets were used to
create a PC space, whereupon individuals whose parents
and grandparents were known to have been born in
Denmark (based on Danish birth records) were used as a
reference for removing individuals deviating from the
multivariate mean of the joint distribution of the ﬁrst ten
principal components (PCs). This was then repeated using
only the remaining iPSYCH individuals to account for
subtle within-population differences. Individuals were also
removed based on missingness (1%) and abnormal hetero-
zygosity or ambiguous sex, based on genetic markers.
Individuals who were identiﬁed as duplicates were also
removed. Lastly, individuals found to be related to others
(ﬁrst and second degrees) were removed, whereby cases and
then individuals with a higher genotype call rate were
prioritized. Following this, a new PCA was performed and
the new PCs were used as covariates in downstream ana-
lyses. The total number of individuals in the post-QC
sample in this study was 65,534. Since this study did not
use the SNP data directly, we discuss them only brieﬂy
here. Samples were genotyped on the Illumina Inﬁnium
PsychArray v1.0. The QC procedure employed consisted of
the following thresholds: SNP missingness of 5% (before
sample removal); subject missingness of 2%; autosomal
heterozygosity deviation | Fhet | of 0.2; SNP missingness of
2% (after sample removal); and SNP Hardy-Weinberg
equilibrium p-value of 10−6.
The phenotype groups included in this study were as
follows: controls (no psychiatric or neurodevelopmental
diagnoses, as per ICD-10 codes F00-F99); schizophrenia
cases (F20); bipolar disorder (BPD) cases (F30-F31); single
and recurrent depressive disorder cases (F32-F33); anorexia
nervosa cases (F50.0); ASD cases (F84.0, F84.1, F84.5,
F84.8, and F84.9), ADHD cases (F90.0) and intellectual
disability (ID) cases (F70-F79). The ﬁrst six case categories
were the primary phenotype groups in the iPSYCH case
sample, together with a random population sample from
which the controls were selected. A diagnosis of ID is a
secondary phenotype in this sense. Diagnoses are based on
records dating up to 2013 from the Danish Psychiatric
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Central Research Register. While controls have no psy-
chiatric diagnosis in the register, some cases are diagnosed
with more than one disorder, and we discuss one example of
this relevant to our results. Otherwise, we did not exclude
individuals with comorbid diagnoses. Sample sizes are
given in Table 1. For subtypes of ID and for anorexia only,
diagnoses from the Danish National Patient Register that
were not present in the psychiatric register were available
for a small number of individuals (30 for ID and 83 for
anorexia). For signiﬁcant HLA associations identiﬁed in
this study, we repeat the analyses after excluding the rele-
vant group of discordant individuals.
Generation and processing of exome data
A subset of the iPSYCH sample was exome-sequenced.
Sequencing libraries were produced using a custom adapta-
tion of the Illumina Rapid Target Kit (Illumina ICE Broad
Exome) and sequenced on Illumina Hiseqs. The raw reads
were mapped using bwa aln (v5.9) with the parameters -q 5 -l
32 -k 2 to GRCh37 including unplaced and unlocalized
contigs and Epstein-barr (NC_007605.1). Thereafter PCR
duplicates were removed using picard MarkDuplicates,
combined per sample and realigned across indels using
GATK IndelRealigner [19].
Imputation of HLA alleles
SNP data were used to impute HLA types with a four-digit
resolution for: HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-
DQA1, HLA-DQB1, and HLA-DPB1. The HLA imputation
was performed with HIBAG v1.3 [20] using a pre-trained
four-digit European ancestry model based on the PsychArray-
B genotype platform (downloaded from: http://zhengxwen.
github.io/HIBAG/hibag_index.html). The alleles were impu-
ted based on 385–556 sites, depending on the locus, and
each wave was imputed separately. Waves were thereafter
combined. Additionally, we called class I alleles from the
exome-sequencing data of 500 randomly sampled individuals
using Polysolver [21]. When running Polysolver, a reference
dataset of Caucasian individuals was used, without
frequencies. Kolmogorov-Smirnov tests were performed in R
[22] comparing posterior probability distributions from
HIBAG for alleles highlighted in the statistical analyses as
described below against all other alleles for the particular
locus. The posterior probability threshold for HLA alleles
used in downstream analyses was 0.9.
The iPSYCH data are stored in a national HPC facility in
Denmark. The iPSYCH initiative is committed to providing
access to these data to the scientiﬁc community, in accor-
dance with Danish law. Researchers may be granted access
upon request to the iPSYCH management.
Statistical analysis
Allele counts for each HLA subtype are used as variables in
two types of analyses: a gene-based test and an allele-
speciﬁc test, with covariates for: age, age squared (to
account for non-linearity with age), sex, and the ﬁrst ten
PCs from the PCA, to account for differences in genetic
ancestry. In both analyses, HLA alleles are coded as allele
counts (0, 1 or 2). The iPSYCH samples in the ﬁnal dataset
were genotyped in 23 waves. In order to determine whether
the genotyping waves had any effect on association, we
performed regressions of the wave category on the HLA
alleles (23 regressions in total, where in each one a given
wave is tested against all other waves). As the waves were
selected by year of birth, age (and psychiatric diagnosis)
could be confounded with them. To test for any independent
effect of the waves, we performed the regressions in the
psychiatric control subset with a covariate for age. The
results were subject to FDR correction. None of the HLA
subtypes showed signiﬁcant association with any wave
(minimum q= 0.394). We therefore do not use a covariate
for wave, but for the top associations we do examine how
adding this covariate affects the result. In all (non-stratiﬁed)
analyses, groups with a psychiatric or neurodevelopmental
diagnosis are compared against controls (with no psychia-
tric or neurodevelopmental diagnosis). For ID, we also
perform “stratiﬁed” analyses for each of the other diagnoses
(note that these are not mutually-exclusive subsets of the
original sample). All statistical analyses are implemented in
R, and the regressions were performed with the glm
function.
Gene-based tests
The gene-based tests serve as omnibus tests and assess
whether the inclusion of all alleles (as separate variables) in
the model improves the model signiﬁcantly. We do not
Table 1 Sample sizes across controls and case groups
Group Sample count
Controls 19,645
ASD 12,331
ADHD 14,397
Schizophrenia 2401
BPD 1391
Single and recurrent depression 18,511
Anorexia 2551
ID 3175
ASD excluding ID 10,579
ID excluding ASD 1423
Both ASD and ID 1752
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draw conclusions on speciﬁc alleles from those tests, but,
rather, we use them as a starting point for potential post hoc
tests. They consist of logistic regressions including all
alleles (as separate variables, i.e., each individual has a
count of 0, 1 or 2 alleles per each imputed allele passing
QC) of a given HLA gene plus the covariates (full model) or
the covariates alone (null model). The two models are
compared using a likelihood ratio test (LRT). Reported p-
values are from the LRT chi-squared statistics. These ana-
lyses thus determine the overall association of a given HLA
gene with the disorder of interest by assessing whether the
inclusion of the allele variables signiﬁcantly explains more
of the variance in the outcome. To account for multiple
testing, we employ a Bonferroni correction but also con-
sider false discovery rate (FDR) q-values, as implemented
in QVALUE v1.0 [23]. All p-values from the gene-based
tests across all disorders were used in the generation of q-
values using the bootstrap method.
Allele-speciﬁc tests
We perform post hoc allele-speciﬁc tests for genes
that show a signiﬁcant association with at least one
disorder, where each allele of the gene is tested separately
in a logistic regression with the same covariates (and the
relevant disorder as the outcome). Reported p-values
pertain to whether the coefﬁcient (log-odds ratio) for
the allele is different from zero (Wald test). For these
tests we report the odds ratio (OR) and 95% conﬁdence
interval (CI). We also use this approach to test for
association with alleles previously reported to be
implicated in the investigated disorders. In addition to a
Bonferroni correction, we compute q-values based on
the distributions of p-values for all successfully tested
alleles of each gene, both per HLA gene-disorder asso-
ciation and across all groups. This applies to genes
implicated in the gene-based analyses as well as genes
implicated in previous studies, in the replication analyses.
Where possible, the bootstrap method is used; this
depended on the number of p-values and their distribu-
tion. Otherwise, we set the tuning parameter λ= 0,
resulting in a conservative analysis. Lastly, for alleles
highlighted in the above analyses, we perform permuta-
tion tests using glmperm [24] in R with 10,000 permu-
tations. Figure 1 includes an outline of the study design
and performed analyses.
Imputation of HLA 
alleles using HIBAG
• Informed by basic SNP 
QC.
Gene-based 
(omnibus) tests for 
HLA genes and 
disorders
• Informed by general 
iPSYCH sample QC to 
include only unrelated 
Danish individuals.
Allele-based (post 
hoc) tests for alleles 
of genes showing 
association with at 
least one disorder
• Alleles were also tested 
for potential genotyping 
wave associations.
Additional checks 
and tests for alleles 
highlighted in the 
previous step
• An examination of the HLA imputation posterior probability 
distributions to preclude imputation artifacts.
• For HLA class I alleles, a concordance check with an imputation 
method based on exome sequencing, in a subset of the sample.
• An association test in a stratified model for iPYSCH secondary 
phenotypes (intellectual disability).
• An association test which included a covariate for genotyping wave.
Association testing 
for implicated alleles 
in different 
phenotype subsets
• Allele-specific tests using case 
subsets of relevant phenotypes.
• Additional association tests, 
excluding samples with discordant 
phenotype information in the two 
Danish registries.
• A permutation test to account for 
low allele frequencies.
Fig. 1 An outline of the study design and performed analyses. See Methods section for more detailed information
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Results
Imputation of HLA alleles in the Danish cohort
For the three HLA class I loci (A, B, and C) and four HLA
class II loci (DPB1, DQA1, DQB1, and DRB1) iPSYCH
genotype chip data were used to impute HLA alleles with
HIBAG. We imputed two alleles at each locus resulting in
diploid allele calls for each of the seven HLA genes and
ﬁltered for a posterior probability threshold of 0.9 (Fig. 2a).
This approach removed between 4852 and 25,331 indivi-
duals for speciﬁc HLA loci, with HLA-A having the largest
number of high-conﬁdence imputations, and HLA-DRB1
having the lowest (Fig. 2b). In general, HIBAG was able to
call alleles with high posterior probabilities, but for some
alleles low posterior probabilities were obtained (Supple-
mentary Figs. S1–S2), and the latter were more likely to be
removed. To validate the imputations, we used PolySolver to
call class I alleles for 500 randomly-sampled individuals for
whom we have exome-sequencing data. Here we found a
Fig. 2 Imputation of HLA alleles. a Posterior probability densities per
HLA locus from HIBAG imputation. HLA class I are solid lines, HLA
class II loci are represented as dotted lines, vertical dotted line at 0.90
represents ﬁltering threshold. Color coding: A: red, B: blue, C: green,
DPB1: magenta, DQA1: orange, DQB1: black and DRB1: brown.
b Number of samples that were removed (no call) or kept (call) for the
seven HLA loci, color coding as in (a). c Correlation between the total
number alleles called and the number of homozygous individuals for a
given allele. Each allele is color coded according the locus, color as in
(a). d Number of alleles called per sample after ﬁltering for posterior
probability. The maximum number of alleles that can be called per
sample across all seven loci is 14
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concordance rate of 0.981, 0.986, and 1.00 for HLA-A, HLA-
B, and HLA-C, respectively, showing a very good overlap
between the two methods and datasets. Furthermore, we
investigated the rate of homozygous calls and found, as
expected, a quadratic correlation between the total number of
alleles called and the number of individuals homozygous for
a particular allele (R2-adjusted: 0.99, p < 10−16) (Fig. 2c). In
the ﬁnal set of imputed HLA-alleles, 56,535 individuals
(86.3%) had alleles that had passed QC for at least 5 loci
(Fig. 2d). In total, the following numbers of alleles were
imputed for HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-
DQA1, HLA-DQB1, and HLA-DRB1, respectively: 31, 65,
30, 21, 15, 17, and 43. After allele and sample QC, the
following numbers of alleles remained: 24, 42, 21, 15, 12,
14, and 27. The distributions of HLA allele counts and fre-
quencies in case and control groups can be found in Sup-
plementary Table S1. Supplementary Table S2 contains the
amino acid sequence alignments for exons 2–3 (class I genes)
or exon 2 (class II genes), the antigen binding domains,
which correspond to the HLA allele resolution in this study,
for all imputed alleles passing the allele QC, as well as the
genomic sequence of all individual HLA alleles at a full
resolution from http://hla.alleles.org/alleles/text_index.html
(accessed on 6 March 2019) [25, 26], for reference purposes.
Associations of HLA alleles with
neurodevelopmental or psychiatric disorders
Gene-based LRT chi-squared p-values for all disorders are
given in Table 2. After a strict Bonferroni correction for 49
tests, only the association between HLA-DPB1 and ID
survived. FDR correction, however, results in three sig-
niﬁcant tests: ID with HLA-B (q= 0.047) and HLA-DPB1
(q= 0.004), and ASD with HLA-DPB1 (q= 0.047). Our
post hoc analyses thus investigated which alleles in HLA-B
and HLA-DPB1 might be individually signiﬁcantly asso-
ciated with ID or ID and ASD, respectively. In the frame-
work of the Bonferroni correction, that is, if only the
association between HLA-DPB1 and ID is considered, one
allele, DPB1*1501 ID (p= 0.00099, OR= 0.41, 95% CI:
0.23, 0.67), remains signiﬁcant after correction for the
number of HLA-DPB1 alleles tested (N= 15). In the fra-
mework of FDR-signiﬁcant associations, for HLA-B we
found one allele, B*5701, to be signiﬁcantly associated with
increased risk of ID (p= 0.00016, q= 0.004, OR= 1.33,
95% CI: 1.14, 1.53). DPB1*1501 was signiﬁcantly asso-
ciated with reduced risk in ID (q= 0.015). The same allele
showed a near-FDR-signiﬁcant association in the same
direction in ASD (p= 0.0094, q= 0.07, OR= 0.72, 95%
CI: 0.56, 0.92). The above q-values were computed per
gene-disorder association due to the large difference in
allelic variation across genes; when p-values across all
gene-disorder groups are considered simultaneously, the
lowest q-value was 0.13, obtained for the above three allele-
disorder associations and six others, suggesting that 1–2 of
them are likely to be false positives.
To ensure that these associations were not spurious
artifacts of the imputation process, we investigated the
posterior probability distributions from HIBAG for these
two alleles. We found their posterior probability distribution
to have different trends compared to all other alleles from
the same loci (Kolmogorov-Smirnov test: p < 10−16).
Examining the direction of the trend, we found no evidence
of their being worse (p < 10−16), but there was evidence of
their being better (p= 1 and p= 0.11), corresponding well
to the actual distributions (Supplementary Fig. S3). This can
be seen in the ﬁgure, where, in both cases, the red line,
corresponding to the allele in question, shows a distribution
that is right-shifted compared to all the other alleles of the
same gene (blue line), representing a higher density towards
posterior probabilities closer to 1. The number of alleles that
these two were compared to were 54 alleles for B*5701 and
20 for DPB1*1501 (all alleles passing the allele QC for the
two genes). Additionally, we investigated the concordance
for B*5701 speciﬁcally and found a concordance rate of 1
between HIBAG and PolySolver for this allele (39 alleles
called in 500 individuals). We are not able to determine
concordance for DPB1*1501, as PolySolver does not call
Table 2 Association p-values
for the gene-based tests across
all disorders and HLA genes
Disorder HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQA1 HLA-DQB1 HLA-DPB1
ADHD 0.9473 0.4631 0.7223 0.7758 0.694 0.7355 0.1623
Anorexia 0.8448b 0.1232b 0.9765 0.8317 0.6557 0.2731 0.286
ASD 0.3388 0.708 0.613 0.2499 0.1922 0.5358 0.00253a
BPD 0.5202 0.9946b 0.1097 0.2729b 0.3441 0.2113 0.5345
ID 0.1143 0.003425a 0.3553 0.6607b 0.7052 0.182 0.0001035a
Schizophrenia 0.1392 0.2337 0.8546 0.6014 0.834 0.4088 0.177
Single and recurrent
depression
0.9107 0.5133 0.4299 0.3706 0.2282 0.04346 0.2829
aTests that obtained q ≤ 0.05
bTests where, in the full model, the algorithm did not converge or extreme probabilities were obtained
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HLA class II genes. The p-values of the allele-speciﬁc tests
for all tested alleles in these gene-disorder groupings can be
found in Supplementary Table S3. Since ID was not one of
the primary phenotypes for which iPSYCH cases were
selected, there could be some ascertainment bias with ID in
the sense that more individuals with ID in the sample are
also expected to have another iPSYCH diagnosis than if
they had been selected primarily for ID. We therefore tested
both DPB1*1501 and B*5701 for association with ID only
within iPSYCH cases for each of the other six disorders
(separately). For DPB1*1501, the only nominally sig-
niﬁcant association (p= 0.01) was within ASD cases. For
B*5701, there were two nominally signiﬁcant associations,
with ADHD (p= 0.01) and depression (p= 0.049). In all
cases the observed association had the same trend with ID
as in the non-stratiﬁed analyses. Similarly, adding a cov-
ariate for wave for the associations of DPB1*1501 and
B*5701 with ID did not alter the results signiﬁcantly, with
ORs of 0.39 and 1.32, and p-values of 0.00052 and
0.00021, respectively.
While the DPB1*1501 association with ASD is only
nominally signiﬁcant, given the phenotypic overlap between
ID and ASD, it is interesting that the same allele is at least
nominally associated with both disorders in the same direc-
tion. We therefore investigated this association further by
repeating both types of tests using the subset of individuals
with ASD but without ID, the subset of individuals with ID
but without ASD, and the subset of individuals with both
diagnoses, labeled ASD+ID−, ASD−ID+, and ASD+ID+,
respectively. Note, while these analyses allowed us to
investigate which condition drove the observed associations,
they also resulted in reduced samples sizes (Table 1). The
gene-based tests for HLA-DPB1 with ASD+ID−, ASD−ID+,
and ASD+ID+ remained at least nominally signiﬁcant, with p-
values of 0.0046, 0.028, and 0.0012, respectively. The gene-
based test for HLA-B with ASD−ID+ obtained a p-value of
0.0036, and the test with ASD+ID+ obtained a p-value of
0.059. The allele-speciﬁc analyses showed that DPB1*1501
was not signiﬁcantly associated with ASD+ID− (p= 0.058,
OR= 0.78, 95% CI: 0.61, 1.01) or with ASD−ID+ (p= 0.09,
OR= 0.56, 95% CI: 0.27, 1.03), but it was signiﬁcantly
associated with ASD+ID+ (p= 0.003) and in the same
direction as before (OR= 0.29, 95% CI: 0.11, 0.6). In con-
trast, B*5701 showed an even stronger association than
before with increased risk of ASD−ID+ (p= 1.37 × 10−5,
OR= 1.54, 95% CI: 1.26, 1.86), despite the fact that the
subset of individuals with a diagnosis of ID but without a
diagnosis of ASD was the smallest of the three in terms of
sample size (Table 1). It was not signiﬁcantly associated with
ASD+ID+ in the allele-speciﬁc test (p= 0.167, OR= 1.15,
95% CI: 0.94, 1.41). A summary of all follow-up allele-
speciﬁc associations that were at least nominally signiﬁcant
(p ≤ 0.05) can be found in Table 3. Considering these tests, the
associations between DPB1*1501 and ASD+ID+ and
B*5701 and ASD−ID+ survive Bonferroni correction for 10
tests. None of the associations in Table 3 were much
affected by the exclusion of the 30 register-discordant ID
cases (in fact they all obtained slightly more signiﬁcant
p-values). Given the low allele frequencies particularly of
DPB1*1501 but also of B*5701, we performed permutation
tests, which could help address this issue. We obtained
signiﬁcant permutation p-values for DPB1*1501 with ID
and ASD+ID+ (p= 2 × 10−4 and 4 × 10−4, respectively),
and for B*5701 with ID and ASD−ID+ (p= 2 × 10−4 in
both cases).
Replication of previous HLA associations with ASD,
ADHD, and schizophrenia
We also attempted to replicate previously reported asso-
ciations with ASD, ADHD, and schizophrenia, testing all
the alleles of speciﬁc genes based on previous implication
of any allele of a given gene, rather than individual alleles.
We chose this approach because many studies reported
associations with serotypes or alleles using a two-digit
resolution, rather than alleles/subtypes with a four-digit
resolution, as used in this study. All allele-speciﬁc tests
were subject to FDR correction, as described previously.
For ASD and ADHD, we tested a subset of the genes (one
or more of HLA-A, HLA-B, and HLA-DRB1), as previously
reported associations between HLA genes and those dis-
orders pertained mostly to those genes [5–8]. For schizo-
phrenia, we tested the alleles of all genes, as associations
with alleles of all of the HLA genes in our study have been
reported in at least one study [10]. The full results of the
replication analysis can be found in Supplementary
Table S4. All alleles had q > 0.05 both in the gene-disorder
groups and across all groups; similarly, no association
Table 3 Nominally-signiﬁcant
associations (p ≤ 0.05) from the
follow-up allele-speciﬁc tests
Disorder Gene Allele p-value OR 95% CI for OR
ID HLA-B B*5701 0.00016 1.33 1.14, 1.53
ID HLA-DPB1 DPB1*1501 0.00099 0.41 0.23, 0.67
ASD HLA-DPB1 DPB1*1501 0.0094 0.72 0.56, 0.92
ASD+ID+ HLA-DPB1 DPB1*1501 0.003 0.29 0.11, 0.6
ASD−ID+ HLA-B B*5701 1.37 × 10−5 1.54 1.26, 1.86
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survived Bonferroni correction. Nominally-signiﬁcant
associations (p ≤ 0.05) can be found in Table 4. None of
the associations for ASD or ADHD in Table 4 correspond to
the previously implicated alleles/serotypes, based on WHO
grouping from the HLA Dictionary [27]. For schizophrenia,
there is a nominally-signiﬁcant positive association with
DQB1*0604; a negative association with DQB1*0602 and
schizophrenia in African Americans has been reported [28].
DRB1*0404 is negatively associated with schizophrenia in
our study. This allele belongs to the serotype group DR4,
which has been shown to be negatively associated with
schizophrenia in two studies [29, 30]. Given the year of
publication of the latest extensive review article, we used
PubMed to search for schizophrenia studies that mentioned
signiﬁcant associations with the HLA alleles in Table 4 not
mentioned by Wright et al. For A*0101, which belongs to
serotype A1 and had a protective effect in our study, the
previous literature is inconclusive as to its effects in schi-
zophrenia, with some studies ﬁnding it increased risk and
others ﬁnding it reduced risk [31].
Discussion
Taken together, the results of the HLA-DPB1 analyses in the
various ASD and ID subgroups suggest that DPB1*1501
has a protective effect which can be identiﬁed mainly when
comparing mentally-healthy controls with individuals with
a severe phenotype consisting of a diagnosis of both ASD
and ID, and it could be that it was mostly the latter group
that was driving the previous associations with this allele.
DPB1*1501 is a rare allele and it has not been extensively
written about in the literature. A nominally signiﬁcant
association (not surviving correction for multiple testing)
was reported for this allele in the autoimmune disease
chronic idiopathic thrombocytopenia [32]. Even though the
results of this study are not conclusive, it might be worth to
mention the connection between autoimmunity and neuro-
developmental disorders such as ASD, which has
been identiﬁed in both Danish and Swedish population
studies [33, 34]. In another study, the protein product of
HLA-DPB1 has been shown to co-precipitate with a
biologically-active form of the macrophage migration
inhibitory factor (MIF) [35]. MIF acts as an inﬂammatory
cytokine, and it has been implicated in inﬂammatory and
autoimmune diseases [36]. Interestingly, a connection
between MIF and autism has been reported, whereby higher
levels of plasma MIF were correlated with autistic behavior
[37]. While the functional mechanism behind the associa-
tion of DPB1*1501 with reduced risk of a severe ASD-ID
comorbidity is unclear, this and the above independent
associations between HLA-DPB1, MIF, and neurodevelop-
mental disorders suggest a possible role for this gene in
the etiology of ASD and ID. Additionally, a study of
biomarkers for early detection of schizophrenia reported
signiﬁcantly altered levels of plasma MIF in a panel of
blood-based biomarkers [38].
The association of increased risk with B*5701 was
observed in all investigated ID groups except for the group
in which all cases had a comorbid diagnosis of ASD. It
seems that this association is driven by individuals who
have ID but not ASD. This may suggest that B*5701 is a
risk allele speciﬁc to a form of ID that is distinct from ASD
and is not diagnosed together with it. However, there is also
some association signal for this allele within ADHD cases
and depression cases. Unlike the associations of HLA-DPB1
with ASD and ID, the gene-based tests for HLA-B with
ADHD or depression are not signiﬁcant. Nonetheless, it is
possible that the association with B*5701 in this sample is
inﬂuenced by the presence of a diagnosis of ADHD or
depression in addition to ID. Regarding any functional
studies of this allele, it is known to be associated with
hypersensitivity to an anti-retroviral drug [39]. B57 was
noted in a study of speciﬁc language impairment (protective
effect), although this association did not survive FDR cor-
rection [40]. We note again that, when a strict multiple
testing correction (Bonferroni correction) was followed,
only the association between DPB1*1501 and ID survived.
We did not ﬁnd FDR-signiﬁcant evidence for replication
for previously reported associations between HLA alleles
and ASD, ADHD, or schizophrenia. In the ADHD and ASD
studies mentioned above, the sample sizes were small
(fewer than 200 ASD cases in studies implicating HLA-A
and HLA-DRB1 alleles, and fewer than 400 cases in the
study implicating HLA-B; for ADHD, the study implicating
HLA-DRB1 included fewer than 50 cases). In contrast, our
Table 4 Nominally-signiﬁcant associations (p ≤ 0.05) from the
replication analysis; p-values and q-values in this table are rounded
up to the third decimal place
Disorder Allele WHO-assigned OR p-value
ADHD DRB1*1101 DR11 0.40 0.029
ASD A*1101 A11 1.1 0.016
ASD B*2702 B27 2.15 0.005
ASD DRB1*0301 DR17 0.91 0.015
ASD DRB1*1101 DR11 0.38 0.029
Schizophrenia A*0101 A1 0.89 0.019
Schizophrenia A*3402 A34 12.01 0.042
Schizophrenia A*6801 A68 1.17 0.048
Schizophrenia B*4701 B47 2.09 0.005
Schizophrenia B*0801 B8 0.85 0.018
Schizophrenia DQB1*0604 DQ6 1.18 0.013
Schizophrenia DRB1*1104 DR11 1.57 0.034
Schizophrenia DRB1*0404 DR4 0.39 0.046
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sample sizes for ASD and ADHD are larger than 10,000
post-QC The only nominally-signiﬁcant association that
showed the same trend of association was with
DRB1*0404, which belongs to the DR4 serotype, and
schizophrenia, where the allele was protective. However,
even this association, found by several studies, was not
always replicated by others [41]. Thus, our results by large
do not provide strong evidence of replication for most
previously reported associations between ASD, ADHD, and
schizophrenia and HLA genes. The lack of signiﬁcant
association between schizophrenia and HLA alleles in this
large-scale study of a homogeneous population is not in line
with many previous studies and requires further con-
sideration. There could be several reasons for this dis-
crepancy. Firstly, our sample size was much larger than in
previous studies, and, with some studies having very small
sample sizes, that could have led to false positives in those
studies (the sample sizes in the studies that reported the
association with DR4, for example, were quite small: fewer
than 100 cases in one, and fewer than 300 cases in the other,
compared to more than 2000 cases in our study). Differ-
ences in study design might also contribute to this effect:
the statistical models used, the resolution of the HLA typ-
ing, the use of grouped alleles, based on serological activity,
or individual alleles, and population-related differences
could all potentially explain at least some of these differ-
ences. For example, a recent study that found an extremely
signiﬁcant association with schizophrenia used SNPs and
not HLA types, and the index SNP that fell within the HLA
region was not inside a known HLA gene, which may
suggest a different mechanism underlying this association
[42]. With regards to population differences, it should be
mentioned that the HLA region varies greatly between
different populations due to its evolutionary importance
[43–45], which could also have an impact on association
studies. Lastly, schizophrenia has been associated with
excess occurrence of infections and autoimmune diseases
[46], the latter of which also show association with HLA
genes; however, this association might be due to environ-
mental factors or other immune-related genes not captured
by the HLA region itself; it has been previously shown that
a polygenic risk score for schizophrenia does not predict
risk of acquiring infections [47].
Strengths and limitations
Our study cohort is population-based and genetically
homogenous. It includes a larger sample than most immu-
nogenetic studies of psychiatric and neurodevelopmental
disorders, even for our smaller case groups, and diagnoses
based on nation-wide criteria. As such, it offers a unique
opportunity to study the role of the HLA genes in the
etiologies of psychiatric and neurodevelopmental disorders.
However, we note that for some of the diagnoses, namely the
adult-onset ones, this sample might be relatively young. Our
large sample sizes allowed us to examine rare alleles, but
this, in turn, makes it hard to ﬁnd suitable replication cohorts.
We employed strict QC measures for both the imputation and
association analyses, but we acknowledge that our results
should be replicated in other studies. Lastly, it should be
mentioned that in some cases alleles across more than one
HLA gene may act in concert to increase or reduce risk.
Given the approach employed in this study, we analyzed a
large number of alleles and phenotypes and did not examine
haplotypes across genes, but this can provide an interesting
avenue of research in studies focusing on speciﬁc variants.
We hope our study will prompt further investigations and
make psychiatric cohorts in general and ID cohorts in parti-
cular more accessible. In conclusion, this study is, to our
knowledge, the largest HLA association study for psychiatric
and neurodevelopmental disorders. The results implicate
HLA genes in the etiologies of ASD and ID. Furthermore,
our study highlights the importance of large samples and
consistent phenotypes in HLA association studies, as we did
not obtain signiﬁcant evidence of replication for previously-
reported associations. Further studies will be required both to
replicate the associations we have found and to elucidate the
molecular mechanisms that underlie them.
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